Answers are grounded in this paper and cite their sources.
Systematic review explores tirzepatide's effects on weight and glycaemic control in adults with T1D, indicating further research is necessary.
Tirzepatide may be a promising investigational adjunct in selected adults with T1D and overweight or obesity, particularly for weight reduction. However, current evidence remains insufficient to establish durable glycaemic benefit or long-term safety. Larger randomized trials are needed.
No takes yet. Share an insight, caveat, or question.
Acucella et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: